Table 2. Cancer risk following organ transplantation in Sweden, 1970–1997.
| Cancer site (ICD-7) | Observed no. cases | SIR | 95% CI |
|---|---|---|---|
| Overall | 692 | 4.0 | 3.7–4.4 |
| Lip (140) | 40 | 53.3 | 38.0–72.5 |
| Oral cavity (141–144) | 11 | 5.5 | 2.7–9.8 |
| Pharynx (145–146) | 3 | 3.1 | 0.6–9.1 |
| Oesophagus (150) | 5 | 3.2 | 1.1–7.5 |
| Stomach (151) | 12 | 2.3 | 1.2–4.1 |
| Small intestine (152) | 1 | 1.1 | 0.0–6.2 |
| Colon (153) | 25 | 2.3 | 1.5–3.4 |
| Rectal (154.0+154.1) | 14 | 1.9 | 1.0–3.2 |
| Adenocarcinomas | 9 | 1.4 | 0.7–2.6 |
| Squamous cell carcinoma | 4 | 10.2 | 2.8–26.0 |
| Liver, primary (155) | 4 | 1.1 | 0.3–2.8 |
| Pancreas (157) | 4 | 0.9 | 0.3–2.3 |
| Nose, middle ear (160) | 2 | 6.8 | 0.8–24.5 |
| Larynx (161) | 3 | 2.5 | 0.5–7.3 |
| Lung (162) | 24 | 1.7 | 1.1–2.5 |
| Mediastinum (164) | 1 | 42.9 | 1.1–239 |
| Breast (170) | 24 | 1.0 | 0.6–1.5 |
| Cervix uteri (171) | 5 | 2.0 | 0.7–4.7 |
| Cervix in situ | 52 | 1.3 | 1.0–1.8 |
| Ovary (175) | 9 | 2.0 | 0.9–3.8 |
| Vulva and vagina (176) | 11 | 20.9 | 10.4–37.4 |
| Vulva | 9 | 26.2 | 12.0–49.8 |
| Vagina | 2 | 16.4 | 2.0–59.3 |
| Prostate (177) | 20 | 1.1 | 0.7–1.7 |
| Testis (178) | 3 | 2.3 | 0.5–6.6 |
| Kidney (180) | 28 | 4.9 | 3.3–7.1 |
| Bladder (181) | 20 | 2.3 | 1.4–3.6 |
| Malignant melanoma (190) | 14 | 1.8 | 1.0–3.0 |
| Nonmelanoma skin cancer (191) | 278 | 56.2 | 49.8–63.2 |
| Eye (192) | 1 | 2.0 | 0.0–10.9 |
| Brain (193) | 7 | 1.0 | 0.4–2.1 |
| Thyroid (194) | 6 | 3.8 | 1.4–8.2 |
| Connective tissue (197) | 3 | 2.3 | 0.5–6.7 |
| Non-Hodgkin's lymphoma (200+202+204.1) | 45 | 6.0 | 4.4–8.0 |
| Hodgkin's disease (201) | 2 | 2.2 | 0.3–8.1 |
| Multiple myeloma (203) | 6 | 2.7 | 1.0–5.9 |
| Lymphocytic leukaemia (204) | 3 | 1.8 | 0.4–5.1 |
| Myeloic leukaemia (205) | 5 | 2.9 | 0.9–6.7 |
Observed number of cases, SIR (SIR) and 95% confidence intervals (CI) by cancer site and type.